Participated · Equity · Jul 2026

Atoms is presented as a rebranded holding company founded by Travis Kalanick that consolidates work he began after leaving Uber, including his CloudKitchens venture. The company has acquired Pronto, a heavy-industry automation firm led by Anthony Levandowski. Kalanick has described Atoms’ mission as completing a “bits-to-atoms” arc and has said he wants to build a “wheelbase for robots.” The company announced a $1.7 billion financing led by Andreessen Horowitz, signaling substantial external investor support, and Ben Horowitz will join its board. The articles do not provide revenue, user, or other operating metrics, nor do they detail specific product roadmaps or financial allocations beyond Kalanick’s public statements.

Led · Series A · Jul 2026

Founded in 2023 by Ianai Urwicz and Alejandro Rettig, Infinia offers a compliance-focused infrastructure layer that connects local payment networks with stablecoin rails to enable automated settlements and real-time treasury clearing for enterprise customers. The company positions itself as a bridge between traditional banks and digital asset infrastructure in emerging markets. Infinia is a Y Combinator spin-off and lists YC among its investors. Following the $13.5 million Series A, the startup plans to secure additional regulatory licenses and accelerate geographic expansion across Latin America, Africa, and Asia. The funding round was co-led by Bain Capital and Variant Fund with participation from several institutional backers, signaling investor confidence as it scales.

Participated · Series A · Jul 2026

Oratomic is developing both hardware and software for fault-tolerant, utility-scale quantum computers using a neutral-atom qubit architecture. The company argues, based on research with Caltech collaborators, that utility-scale systems may be achievable with roughly 10,000 reconfigurable neutral-atom qubits, and co-founder Manuel Endres has demonstrated arrays of about 6,000 trapped atomic qubits. Led by CEO Dolev Bluvstein, the founding team includes researchers from Caltech, UC Berkeley, Harvard, Amazon and Google, and notable scientists such as John Preskill and Manuel Endres. Oratomic is working on error-correction theory, cryogenic chip packaging, algorithm development and scaling fabrication, and coordinates efforts through global developer networks. The company raised $300 million in a Series A to accelerate hardware fabrication, algorithmic research and to grow its physics and engineering teams. Oratomic has highlighted that sufficiently capable fault-tolerant machines could threaten current public-key encryption and said a fault-tolerant quantum computer is plausible by the end of the decade.

Led · Equity · Jun 2026

STAX Engineering designs and operates a patented, flexible barge-based exhaust capture system that connects to ship stacks from the water to capture and filter emissions without vessel modification or berth-specific infrastructure. Its system is authorized by CARB for container ships, auto carriers, and tankers and is reported to remove up to 99% of particulate matter and 95% of nitrogen oxides. STAX began tanker service testing in early 2025, has supported tanker operations in Southern California since 2024, and has completed over 2,700 vessel calls totalling more than 46,000 treated hours and capturing over 350 tons of pollutants. Recent commercial agreements with IMTT and TransMontaigne expand its Northern California footprint and are expected to support more than 6,400 at-berth service hours through 2031. The company plans to scale deployments across California’s ports to meet demand ahead of CARB’s 2027 tanker compliance deadline. Its current financial position was strengthened by the $150 million financing commitment from Bain Capital to refinance existing debt and fund contracted builds through 2027.

Participated · Series A · Jun 2026

Beeline Medicines is a clinical-stage biotechnology company building a focused pipeline of precision therapies rooted in validated biology. Its lead candidate, afimetoran, is a once-daily oral small molecule that targets toll-like receptors 7 and 8 (TLR7/8). Afimetoran has completed a Phase 1b trial in cutaneous lupus erythematosus and is currently in a Phase 2 study with a readout expected by year-end. The company plans to initiate a pivotal lupus trial following the Phase 2 results. Beeline emerged from stealth concurrent with announcing a $300M Series A financing led by Bain Capital. The company emphasizes durable, meaningful outcomes for patients with significant unmet needs and has assembled a leadership team that includes CEO Saqib Islam, COO and President Badreddin Edris, and CMO Nathalie Franchimont.